Q301 - ClonoSEQ Measurable Residual Disease (MRD) Testing Services

Award Notice Posted

Solicitation number
36C25026Q0104
Agency
Awarded
to Adaptive Biotechnologies Corporation
Set-aside
No set-aside

Opportunity facts

Contract number
36C25026P0251 Federal contract award
NAICS code
621511 Medical Laboratories
Place of performance
Cleveland, Ohio 44106, United States

Notice details come from SAM.gov. Updated .

About this opportunity

The Department of Veterans Affairs Veterans Integrated Service Network 10, through Network Contracting Office 10, awarded a one-year firm fixed price contract to Adaptive Biotechnologies Corporation valued at $243,750.00 to provide ClonoSEQ Measurable Residual Disease (MRD) testing services for the Louis Stokes VA Medical Center. The contract encompasses an estimated 125 FDA-cleared, next-generation sequencing-based MRD tests for blood and bone marrow samples from patients with multiple myeloma, chronic lymphocytic leukemia, and B-cell acute lymphoblastic leukemia, with testing conducted at the contractor's CLIA-certified and CAP-accredited reference laboratory. The performance period runs from December 29, 2025 through December 28, 2026, with electronic delivery of results to VA clinicians within five business days of specimen submission. This testing service supports critical clinical functions including monitoring disease progression, evaluating treatment efficacy, and assessing patient outcomes during cancer therapy.

Notice text

The Department of Veterans Affairs, Network Contracting Office 10, made an award for a one (1) year firm fixed price (FFP) contract with Adaptive Biotechnologies Corporation, 1165 Eastlake Ave. E, Seattle WA, 98109 to provide Clono-Seq Assay testing services for the Louis Stokes VA Medical Center, Pathology & Laboratory Services (PALMS), 10701 East BLVD., Cleveland, OH 44106.

The point of contact is Thomas Bellamy, Contracting Officer, Network Contracting Office 10 - Thomas.Bellamy@va.gov.

Awarded contract 36C25026P0251 to ADAPTIVE BIOTECHNOLOGIES CORPORATION for 243750.00 on 2025-12-30.

Files

File Type Posted
36C25026P0251 Bilaterally Signed.pdf PDF

Notice history

Notice Type Posted
This notice Award Award Notice
Q301 - ClonoSEQ Measurable Residual Disease (MRD) Testing Services Latest special notice Special Notice

Similar open opportunities

Opportunity Agency Set-aside Responses due
Q301--NEW – STX Specialized Molecular Residual Disease Testing NAICS 621511 Veterans Integrated Service Network 17 No set-aside
Q301--Media Fill Testing for Clean Room Compliance - Pharmacy Base 4 years NAICS 541380 Veterans Integrated Service Network 9 No set-aside
Q301--Reference Laboratory Testing Department of Veterans Affairs Multiple VA Medical Centers, United States · NAICS 621511 Veterans Integrated Service Network 2 No set-aside
6640--Electrophoresis Testing for the Albany, Buffalo, and Syracuse VA Medical Centers NAICS 334516 Veterans Integrated Service Network 2 No set-aside
6550--Cepheid GeneXpert Testing Supplies Beckley Vamc Clarksburg Vamc Vamhcs Washington Vamc · NAICS 325413 Veterans Integrated Service Network 5 No set-aside

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity